Selexys Pharmaceuticals Signs CMO Agreement with Cytovance Biologics - - BioPharm International

ADVERTISEMENT

Selexys Pharmaceuticals Signs CMO Agreement with Cytovance Biologics



Cytovance Biologics, a CMO of mammalian and microbial biologics, announced a development and manufacturing agreement for SELK2 with Selexys Pharmaceuticals, an Oklahoma City-based clinical stage biopharmaceutical company.

SELK2 is an investigational humanized monoclonal antibody directed toward the treatment of Crohn’s disease and multiple myeloma. Selexys has contracted Cytovance Biologics as its CMO to provide process development, scale up, and cGMP manufacturing services of SELK2 in support of a Phase I human clinical trial.

Source: Cytovance Biologics

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Harnessing the Power of Modified T Cells to Treat Cancer
October 17, 2014
Lilly to Close Manufacturing Facility in Puerto Rico
October 17, 2014
BioReliance Introduces New Predictive Assays
October 17, 2014
Industry Stakeholders Tackle the Use of Biological Qualifiers at WHO Naming Session
October 16, 2014
Pfizer Ireland Plant Receives ISPE Award
October 16, 2014
Author Guidelines

Click here